CD163 Binding Protein Patent Application

ChangeBridge: Patent Apps - Peptides (C07K)

Published October 11th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085129A1) filed by ECO ANIMAL HEALTH LTD. on October 11, 2023. The application relates to an antibody that binds to porcine CD163, specifically its membrane-bound form.

View original document View source feed page

What changed

This document is a publication of a patent application filed by ECO ANIMAL HEALTH LTD. for an antibody that binds to porcine CD163. The application, identified as US20260085129A1, was filed on October 11, 2023, and claims an antibody that specifically targets the membrane-bound form of porcine CD163 while not significantly binding to its soluble form. It also covers combinations of this antibody with other anti-porcine CD163 antibodies or binding proteins.

This publication does not impose any new regulatory obligations on regulated entities. It serves as a notice of a pending patent application in the field of animal health and biotechnology. Compliance officers in the pharmaceutical and animal health sectors should be aware of this filing as it pertains to intellectual property in the development of treatments targeting porcine CD163.

Source document (simplified)

← USPTO Patent Applications

CD163 BINDING PROTEIN

Application US20260085129A1 Kind: A1 Mar 26, 2026

Assignee

ECO ANIMAL HEALTH LTD.

Inventors

Christine TAIT-BURKARD, Charles Edward OWEN, Hafid Abdelaali BENCHAOUI

Abstract

The present disclosure provides an antibody which binds to porcine CD163, wherein said antibody binds to the membrane-bound form of porcine CD163 on cells and does not bind significantly to the soluble form of porcine CD163. The present disclosure also provides a combination of said antibody with one or more further anti-porcine CD163 antibodies or binding proteins. Preferred combinations are those in which each antibody or binding protein binds to a different epitope in porcine CD163, and wherein said combination of anti-porcine CD163 antibodies or binding proteins are provided in a single construct. Nucleic acid molecules, expression vectors and compositions are also provided.